Victoria Johnson

The FDA has set a PDUFA date of December 30, 2026.

An audio recap of the top 5 stories in healthcare news from the week of 03/02-03/08.

New biologics transform severe asthma and COPD, yet prednisone overuse persists—see practical selection tips and outpatient steroid stewardship gaps.

Experts weigh new biologics including dupilumab, tezepelumab, and depemokimab, and how eosinophils guide real-world prescribing.

February 2026 saw new data and expert interviews from AAAAI 2026.

A new study stratified patients by longitudinal BEC patterns to assess whether variability in eosinophil levels influences response.

Navepegritide, to be marketed as YUVIWEL, is the only FDA-approved treatment providing continuous CNP exposure over its weekly dosing interval.

AAAAI 2026 showcases high-impact clinical trials and innovative sessions, 5 of which are highlighted below.

Claims study suggests dry powder and soft mist COPD inhalers cut exacerbations versus MDIs, offering greener care without added safety risks.

An audio recap of the top 5 stories in healthcare news from the week of 02/15-02/21.

Seralutinib did improve 6-minute walk times and biomarkers, especially in patients with higher-risk disease.

A clinical forum focuses on how advanced practice providers (APP) and clinicians are now navigating how to translate emerging data into real-world practice.

A clinical forum brought together pulmonologists and advanced practice providers to share their experiences navigating the changing COPD and asthma landscape.

An audio recap of the top 5 stories in healthcare news from the week of 02/01-02/07.

This FDA News Month in Review provides a round-up of regulatory decisions from January 2026.

New data presented at EHSF in Malta boasts a reduced proportion of patients with severe HS at 3 years.

January 2025 saw new data and guidelines in asthma, COPD, and pulmonary fibrosis.

The resubmission follows a prior Complete Response Letter (CRL) that identified chemistry, manufacturing, and control (CMC) issues.

An audio recap of the top 5 stories in healthcare news from the week of 01/18-01/24.

GRI-0621 shows promise as a safe, effective treatment for idiopathic pulmonary fibrosis, improving biomarkers and lung function in a Phase 2a trial.

New guidelines on biologic management for severe asthma provide essential recommendations for optimizing treatment choices among clinicians.

An audio recap of the top 5 stories in healthcare news from the week of 01/04-01/10.

Higher accuracy lung biopsy could make a strong impact on lung cancer diagnoses and outcomes.

Experts discussed how biologics revolutionize asthma and COPD management, emphasizing personalized treatment strategies and proactive care.

Despite an OTC approval in 2023, recent data highlights a carry rate of only 10% in the general population.

An audio recap of the top 5 stories in healthcare news from the week of 01/04-01/10.

December 2025 saw new data on asthma therapies and new insights from experts on continuing trends in the field.

Pulmonary arterial hypertension treatment continues to evolve with new therapies and strategies.

The Q4 recap for pulmonology spotlights regulatory and clinical advances across asthma and pulmonary fibrosis.

The pulmonology year in review highlights FDA approvals and pivotal data readouts.